Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-001186
Filing Date
2025-02-14
Accepted
2025-02-14 16:31:18
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9473
  Complete submission text file 0001172661-25-001186.txt   11267
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Subject) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91591 | Film No.: 25629713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 2034090812
Deep Track Capital, LP (Filed by) CIK: 0001856083 (see all company filings)

EIN.: 853360885 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G